Secretin human
Also known as: ChiRhoStim, Human secretin, SCT, SEC, SecreFlo, Secretin
Source Secretin human at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Affiliate link: we earn a commission on purchases made through this link, at no extra cost to you.
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
Human secretin is a synthetic gastrointestinal peptide hormone approved as a prescription injectable for diagnostic purposes. It is administered intravenously to stimulate pancreatic ductal secretion, thereby enhancing magnetic resonance cholangiopancreatography (MRCP) and aiding detection of pancreatic duct abnormalities in patients with pancreatitis.
Mechanism of Action
Secretin binds the G‑protein‑coupled secretin receptor on pancreatic duct cells, activating adenylate cyclase and raising intracellular cAMP. The cAMP surge drives bicarbonate‑rich fluid secretion, which expands the pancreatic ductal lumen and improves imaging contrast during MRCP. The hormone’s action is potentiated by cholecystokinin and modulated by neurohormonal pathways involving vagal reflexes.
What the Research Shows
A phase‑3 multicenter trial (258 participants) showed that secretin‑stimulated MRCP identified pancreatic duct lesions with significantly higher sensitivity than unenhanced MRCP, while maintaining specificity. Adverse events were mostly mild (nausea, abdominal pain, flushing). Multiple double‑blind, placebo‑controlled studies in children with autism spectrum disorders, including a trial of a single synthetic secretin dose, consistently failed to demonstrate behavioral or sleep benefits. A review of 15 randomized trials confirmed the lack of robust efficacy for pervasive developmental disorders. A narrative review highlighted secretin’s physiological role in pancreatic bicarbonate secretion and its experimental use for diagnosing gastrinoma and evaluating chronic pancreatitis pain, but therapeutic benefits remain unproven.
Reported Benefits
Evidence from a large prospective trial supports secretin’s ability to improve the diagnostic yield of MRCP for pancreatic duct abnormalities, potentially reducing the need for invasive endoscopic procedures. The enhancement is achieved without serious safety concerns, as reported adverse events were mild and transient.
Limitations of the Evidence
Clinical trials have not shown secretin to be effective for autism spectrum or pervasive developmental disorders; all randomized studies reported no significant behavioral or sleep improvements. Potential therapeutic uses for chronic pancreatitis pain are speculative, with no controlled data. The diagnostic benefit is limited to settings where MRCP is performed and may not translate to other imaging modalities.
Safety Considerations
In the MRCP study, 38% of participants reported mild adverse events after the baseline MRCP and 68% after the secretin‑enhanced MRCP, most commonly nausea, abdominal discomfort, and flushing. Serious adverse events were rare and largely unrelated to secretin. No severe toxicity has been documented in the cited literature.
How It Is Administered
Secretin is supplied for intravenous injection. In diagnostic protocols, a single bolus dose is given immediately before repeat MRCP imaging. The formulation is a synthetic human peptide (RG1068) prepared for sterile infusion.
Routes of Administration
Goals & Uses
- Pancreatic function testingDiagnosticHigh
- Pancreatic exocrine function testingDiagnosticHigh
- Autism spectrum disorder (investigational)Neurological / InvestigationalLow
- Diagnosis of gastrinoma (Zollinger-Ellison syndrome)DiagnosticHigh
- Facilitation of ERCPDiagnostic / ProceduralHigh
- Magnetic resonance cholangiopancreatography (MRCP) enhancementDiagnostic / ImagingModerate
- Secretin‑enhanced MRCPDiagnostic ImagingModerate
Contraindications
- Hypersensitivity to secretin or excipientsAllergyHigh
- Vagotomy or inflammatory bowel disease affecting duodenumGastrointestinal / SurgicalModerate
- Severe renal impairmentOrganModerateKidney function concerns
- Acute pancreatitisGastrointestinalHigh
- Hypersensitivity to secretin or any excipientsAllergy / ImmunologicHigh
Adverse Effects
- Abdominal discomfortGastrointestinalUncommon
- Anaphylaxis / hypersensitivityImmunologicRare
- HeadacheNeurologicUncommonPain in the head or upper neck
- HypotensionCardiovascularRareLow blood pressure
- FlushingVascularCommonWarmth and redness of the skin
- NauseaGastrointestinalCommonFeeling of sickness or urge to vomit
- Abdominal discomfort / crampingGastrointestinalUncommon
- BradycardiaCardiovascularRare
Drug Interactions
- Proton pump inhibitors (PPIs)Low
- Anticholinergics (e.g., atropine)Moderate
- Other secretagogues (e.g., CCK, gastrin)Moderate
- H2-receptor antagonistsLow
Population Constraints
- PregnancyReproductive SafetyRelative
- Pediatric patientsAgeRelative
- Pediatric (<2 years)AgeRelative
- Patients with known allergy to porcine secretinAllergy / ImmunologicRelative
- Renal or hepatic impairmentOrgan DysfunctionRelative
Regulatory Status
- European UnionApprovedApproved: Pancreatic function testingAvailable in several member states.
- United StatesApprovedApproved: Pancreatic function testing, Secretin‑enhanced MRCPPrescription‑only injectable.
- United KingdomUnknownAvailability and approval status in the UK post-Brexit is not well-documented for human synthetic secretin specifically.
Approved by the FDA as ChiRhoStim (human secretin) for diagnostic use. Also used to aid in the diagnosis of gastrinoma (Zollinger-Ellison syndrome) via the secretin stimulation test.
Evidence & Sources
- Journal ArticleModerateSherman S, et al.2014-01-01T00:00:00.000000Z
- Journal ArticleModerateCarey T, et al.2002-01-01T00:00:00.000000Z
- Journal ArticleModerateChey WY, Chang TM2014-01-01T00:00:00.000000Z
- Journal ArticleModerateHonomichl RD, et al.2002-01-01T00:00:00.000000Z
- Journal ArticleModerateSturmey P2005-01-01T00:00:00.000000Z
- Journal ArticleModeratePatel NC, et al.2002-01-01T00:00:00.000000Z
Frequently Asked Questions
What is secretin used for in clinical practice?
Secretin is approved as an intravenous diagnostic agent to stimulate pancreatic duct secretion, thereby improving the sensitivity of magnetic resonance cholangiopancreatography for detecting ductal abnormalities in pancreatitis patients.
Does secretin help treat autism or improve behavior?
Multiple double‑blind, placebo‑controlled trials and a review of 15 randomized studies have found no evidence that secretin improves behavioral, social, or sleep outcomes in children with autism spectrum disorders.
Are there any safety concerns with secretin injections?
The main reported side effects are mild nausea, abdominal pain, and flushing. Serious adverse events are rare and were not clearly linked to secretin in the studies reviewed.
Can secretin be used to relieve pain in chronic pancreatitis?
While a review mentions secretin as a potential therapeutic for severe pain in chronic pancreatitis, no controlled clinical trials have demonstrated efficacy, so its use for pain remains experimental.
How is secretin administered for imaging?
In the diagnostic setting, a single intravenous bolus of synthetic human secretin is given immediately before a repeat MRCP scan, enhancing ductal visualization.
What is Secretin human used for?
Secretin human is educationally associated with: Pancreatic function testing, Pancreatic exocrine function testing, Autism spectrum disorder (investigational), Diagnosis of gastrinoma (Zollinger-Ellison syndrome), Facilitation of ERCP, Magnetic resonance cholangiopancreatography (MRCP) enhancement, Secretin‑enhanced MRCP. Educational only — not medical advice.
How is Secretin human administered?
Recorded routes of administration: Intravenous.
What are the potential side effects of Secretin human?
Reported adverse effects include: Abdominal discomfort, Anaphylaxis / hypersensitivity, Headache, Hypotension, Flushing, Nausea, Abdominal discomfort / cramping, Bradycardia. This list is not exhaustive — consult a qualified clinician.
Who should avoid Secretin human?
Recorded contraindications: Hypersensitivity to secretin or excipients, Vagotomy or inflammatory bowel disease affecting duodenum, Severe renal impairment, Acute pancreatitis, Hypersensitivity to secretin or any excipients. Consult a qualified clinician before use.